Coherus Oncology, Inc. (CHRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.42+3.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Coherus Oncology grew LOQTORZI revenue to $40.8 million in 2025. Management aims to keep growing this product's sales. Revenue guidance shows growth from $42 million in 2026 to $175 million in 2028. The stock is cheap compared to peers.
The company is still losing money and free cash flow is negative. Revenue growth may slow below analyst expectations. Recent legal and accounting changes add risk.
The market expects about 67% revenue growth next year. Our fair value is around $4.47, close to the current price. We see risk in profitability and execution that the market may not fully price.
Breaks if: LOQTORZI revenue falls below $42 million in FY26
Breaks if: New negative legal or accounting events occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. CHRS is currently loss-making and faces high risk, but it operates in a sector with favorable trends, which could support its growth trajectory.
The market seems to have priced in a low expectations gap, indicating that CHRS is viewed as cheap compared to its peers. There is a low level of fragility in the current regime, suggesting that the stock is not overly sensitive to negative news at this moment.
Management is focused on increasing revenue from LOQTORZI and has shown progress in reducing operating losses. However, the mixed status of advancing clinical developments indicates uncertainty in future performance.
The long-term thesis hinges on several factors, including management's ability to maintain revenue growth, the outcomes of ongoing clinical trials, and external economic conditions that could impact the healthcare sector. Monitoring sector bellwethers will also be crucial.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company is issuing a special dividend. This supports equity financing to help operations. However, the latest earnings report missed expectations. This creates uncertainty about future performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Losses widen or free cash flow remains negative beyond FY28
Breaks if: Total revenue falls below $150 million in FY28
Overall, CHRS presents a complex picture with both opportunities and risks in the coming years. Not investment advice.